Gregory Glenn
Net worth: 87 660 $ as of 2024-03-30
Career history of Gregory Glenn
Former positions of Gregory Glenn
| Companies | Position | Start | End |
|---|---|---|---|
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 2010-07-06 | 2023-03-30 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 2008-08-04 | 2009-12-31 |
| IOMAI CORPORATION | Chief Tech/Sci/R&D Officer | 1997-08-31 | 2007-12-31 |
| Founder | 1997-08-31 | 2007-12-31 | |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - | - |
| Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - | - |
Training of Gregory Glenn
| Oral Roberts University | Doctorate Degree |
| Whitman College | Undergraduate Degree |
Statistics
International
| United States | 7 |
| Austria | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Founder | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
| Walter Reed Army Institute of Research |
- Stock Market
- Insiders
- Gregory Glenn
- Experience
